Innovation in cancer therapeutics and regulatory perspectives

Cancer therapy has undergone a drastic revolution in the past few decades with the introduction of several novel therapies, like immunotherapy (active and passive), stem cell-based therapies, and nanocarrier-based therapies. These therapies have addressed the issues of conventional cancer therapy (c...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2022-05, Vol.39 (5), p.76-76, Article 76
Main Authors: Sharma, Pinky, Jhawat, Vikas, Mathur, Pooja, Dutt, Rohit
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer therapies
Cost of Illness
Drug Approval
Hematology
Humans
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Nanotechnology
Neoplasms - epidemiology
Neoplasms - therapy
Oncology
Pathology
Review
Review Article
Stem Cell Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer therapy has undergone a drastic revolution in the past few decades with the introduction of several novel therapies, like immunotherapy (active and passive), stem cell-based therapies, and nanocarrier-based therapies. These therapies have addressed the issues of conventional cancer therapy (chemotherapy or radiotherapy), like specificity and off-target effects. Further, the introduction of such treatments has improved survival and converted a terminal disease into a more manageable condition. However, many clinical, ethical, and regulatory issues are raised with such novel additions. Several effective therapies are under research but could not come to market or are delayed due to regulatory concerns for marketing approval. The scope of this review encompasses the examination of these regulatory issues and discuss their possible solutions. A practical and flexible regulatory approach, harmonized globally, could help the patients suffering from a terminal illness to lead a quality life.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-022-01677-0